Pipeline
Biographies
Investors
News
Careers
Contact
Vantia Ltd
Southampton
Science Park
1 Venture Road
Chilworth
Southampton
SO16 7NP
United Kingdom
t +44 23 8076 3400
f +44 23 8076 6755
info@vantiatherapeutics.com
Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines.
Vantia was formed in late 2007, and acquired a series of assets & people from Ferring Research Ltd in March 2008.
Vantia is a new company with 21 years experience in small molecule discovery & early development. The new Management Team led by Jim Phillips (CEO) is adding to that a Clinical Development & Commercialisation capability.
Vantia is based in Southampton University's Science Park in the United Kingdom, where our team of 16 scientists have fully equipped facilities for Medicinal Chemistry, DMPK, and Lead Discovery.
Vantia is planning to develop its lead products over the next two years to the point where larger pharmaceutical companies will partner the programs from us.
BioCentury interview with Vantia's CEO, Jim Phillips
26 November 2008
Jim Phillips, CEO of Vantia Therapeutics, talks to BioCentury about Vantia's rapid progress.
» more
Vantia Therapeutics progresses clinical development of lead drug candidates
3 November 2008
Vantia Therapeutics progresses clinical development of lead drug candidates - VA106483 starts Phase II and VA111913
enters clinic, VA118020 in preclinical development.
» more
The Daily Mail
17 October 2008
An article describing the symptoms of dysmenorrhoea and Vantia's clinical trial
of VA111913, appeared in Daily Mail Online
» more
Updated Non-Confidential Overview
Vantia Therapeutics presents an updated, non-confidential Corporate Overview
» more
Job Opportunities
3 October 2008
Vantia Therapeutics is expanding its Development division and has several positions open
» more
New UK R&D company
19 March 2008
Vantia Therapeutics, launched with backing from
MVM Life Science Partners, SV Life Sciences and Novo A/S
» more